Compare AbCellera Biologics Inc (ABCL) vs Gartner Inc (IT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Gartner Inc — how do they compare? AbCellera Biologics Inc trades at $7.19 (market cap $2.35B), while Gartner Inc trades at $136.16 (market cap $9.43B). The key difference: Gartner Inc is far larger — about 4× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | IT | |
|---|---|---|
Market Cap | $2.35B | $9.43B |
Sector | Health | Technology |
52-Week High | $8.12 | $399.15 |
52-Week Low | $2.78 | $125.68 |
Enterprise Value | $1.99B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Gartner (IT) trades at $140.80, up 3.29% today, with a bearish technical signal but strong fundamental profitability. Recent earnings consistently beat estimates, with Q1 2026 EPS of $3.32 exceeding the $2.99 forecast. The company maintains robust margins, including a 68.99% gross profit margin and 11.44% net income margin, though 2025 net cash flow was negative $210.63 million. Analyst consensus price target is $158.00, suggesting potential upside from current levels.
The stock offers value with a P/E of 13.35 and P/S of 1.54, but high P/B of 142.72 and negative cash flow trends pose risks. Competitive pressures in IT consulting and reliance on enterprise spending are headwinds. Institutional sentiment is mixed with 27.78% buy ratings, indicating cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
